20276-1-AP

antibody from Proteintech Group

Targeting: LATS2

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Immunoprecipitation (Data presented on provider website)

Immunohistochemistry (Supportive data in Antibodypedia)

Flow cytometry (Supportive data in Antibodypedia)

Antibody Data

Product number

20276-1-AP

Provider

Proteintech Group

Proper citation

Proteintech Cat#20276-1-AP, RRID:AB_10697657

Product name

LATS2-Specific antibody

Antibody type

Polyclonal

Description

KD/KO validated LATS2-Specific antibody (Cat. #20276-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: FC, IF, IHC, IP, WB,ELISA.

Reactivity

Human, Mouse

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer.

Ying Y, Wu Y, Zhang F, Tang Y, Yi J, Ma X, Li J, Chen D, Wang X, Liu X, Liu B, Luo J, Zheng X, Xie L
Molecular cancer 2024 Apr 24;23(1):79

---

Proximal Tubular Lats2 Ablation Exacerbates Ischemia/Reperfusion Injury (IRI)-Induced Renal Maladaptive Repair through the Upregulation of P53.

Zhang C, Zheng Z, Xu K, Cheng G, Wu H, Liu J
International journal of molecular sciences 2023 Oct 17;24(20)

---

Altering the Cleaving Effector in Chimeric Molecules that Target RNA Enhances Cellular Selectivity.

Suresh BM, Tong Y, Abegg D, Adibekian A, Childs-Disney JL, Disney MD
ACS chemical biology 2023 Nov 17;18(11):2385-2393

---

RNF106 aggravates esophageal squamous cell carcinoma progression through LATS2/YAP axis.

Sun Q, Lu H, Zhang W, Du Y, Liang Q, Zhang Y, Wu J, Zhong M
Archives of biochemistry and biophysics 2023 Jul 1;742:109640

---

Pharmacological Activation of YAP/TAZ by Targeting LATS1/2 Enhances Periodontal Tissue Regeneration in a Murine Model.

Sato A, Suzuki S, Yuan H, Fahreza RR, Wang X, Nemoto E, Saito M, Yamada S
International journal of molecular sciences 2023 Jan 4;24(2)

---

O‑GlcNAcylation mediates endometrial cancer progression by regulating the Hippo‑YAP pathway.

Zhai L, Yang X, Dong J, Qian L, Gao Y, Lv Y, Chen L, Chen B, Zhou F
International journal of oncology 2023 Aug;63(2)

---

Arsenic impairs stem cell differentiation via the Hippo signaling pathway.

Perego MC, McMichael BD, Bain LJ
Toxicology research 2023 Apr;12(2):296-309

---

Identifying LATS2 as a prognostic biomarker relevant to immune infiltrates in human esophageal squamous cell carcinoma.

Zhu M, Liao G, Wang Y, Mo J, Yi D, Zhang Y, Xian L
Frontiers in genetics 2022;13:952528

---

CircRNA CDR1as promotes cardiomyocyte apoptosis through activating hippo signaling pathway in diabetic cardiomyopathy.

Shao Y, Li M, Yu Q, Gong M, Wang Y, Yang X, Liu L, Liu D, Tan Z, Zhang Y, Qu Y, Li H, Wang Y, Jiao L, Zhang Y
European journal of pharmacology 2022 May 5;922:174915

---

The Hippo signaling component LATS2 enhances innate immunity to inhibit HIV-1 infection through PQBP1-cGAS pathway.

He TS, Dang L, Zhang J, Zhang J, Wang G, Wang E, Xia H, Zhou W, Wu S, Liu X
Cell death and differentiation 2022 Jan;29(1):192-205

---

The m(6)A methyltransferase Mettl3 deficiency attenuates hepatic stellate cell activation and liver fibrosis.

Li Y, Kang X, Zhou Z, Pan L, Chen H, Liang X, Chu J, Dong S, Liu C, Yu S, Tu D, Zhang Y, Ge M, Chen W, Xu Y, Zhang Q
Molecular therapy : the journal of the American Society of Gene Therapy 2022 Dec 7;30(12):3714-3728

---

SFN Enhanced the Radiosensitivity of Cervical Cancer Cells via Activating LATS2 and Blocking Rad51/MDC1 Recruitment to DNA Damage Site.

Wang S, Wang Y, Liu X, Yang Y, Wu S, Liu Y
Cancers 2022 Apr 8;14(8)

---

Tumor-derived exosomal miR-19b-3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway.

Chen J, Zhang K, Zhi Y, Wu Y, Chen B, Bai J, Wang X
Clinical and translational medicine 2021 Sep;11(9):e478

---

CYT387, a potent IKBKE inhibitor, suppresses human glioblastoma progression by activating the Hippo pathway.

Wang X, Lu J, Li J, Liu Y, Guo G, Huang Q
Journal of translational medicine 2021 Sep 20;19(1):396

---

Deficiency of large tumor suppressor kinase 1 causes congenital hearing loss associated with cochlear abnormalities in mice.

Nishiyama T, Fujioka M, Saegusa C, Oishi N, Harada T, Hosoya M, Saya H, Ogawa K
Biochemical and biophysical research communications 2021 Jan 1;534:921-926

---

Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling.

Chen Z, Li S, Mo J, Hawley E, Wang Y, He Y, Brosseau JP, Shipman T, Clapp DW, Carroll TJ, Le LQ
JCI insight 2020 Oct 15;5(20)

---

Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis.

Wang X, Cai B, Yang X, Sonubi OO, Zheng Z, Ramakrishnan R, Shi H, Valenti L, Pajvani UB, Sandhu J, Infante RE, Radhakrishnan A, Covey DF, Guan KL, Buck J, Levin LR, Tontonoz P, Schwabe RF, Tabas I
Cell metabolism 2020 May 5;31(5):969-986.e7

---

The Human Novel Gene LNC-HC Inhibits Hepatocellular Carcinoma Cell Proliferation by Sequestering hsa-miR-183-5p.

Lan X, Wu N, Wu L, Qu K, Osoro EK, Guan D, Du X, Wang B, Chen S, Miao J, Ren J, Liu L, Li H, Ning Q, Li D, Lu S
Molecular therapy. Nucleic acids 2020 Jun 5;20:468-479

---

MicroRNA‑93 promotes angiogenesis and attenuates remodeling via inactivation of the Hippo/Yap pathway by targeting Lats2 after myocardial infarctionω.

Ma C, Peng P, Zhou Y, Liu T, Wang L, Lu C
Molecular medicine reports 2020 Jul;22(1):483-493

---

Hippo pathway and tumoral FOXP3 expression correlate with tumor growth in squamous cell carcinoma of the lung.

Won KY, Kim HK, Kim GY, Song MJ, Lim SJ
Pathology, research and practice 2020 Jul;216(7):153003

---

TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZ.

Zhou S, Liu S, Lin C, Li Y, Ye L, Wu X, Jian Y, Dai Y, Ouyang Y, Zhao L, Liu M, Song L, Xi M
Oncogene 2020 Apr;39(18):3710-3725

---

miR-25 Promotes Cell Proliferation, Migration, and Invasion of Non-Small-Cell Lung Cancer by Targeting the LATS2/YAP Signaling Pathway.

Wu T, Hu H, Zhang T, Jiang L, Li X, Liu S, Zheng C, Yan G, Chen W, Ning Y, Li Y, Lu Z
Oxidative medicine and cellular longevity 2019;2019:9719723

---

Essential Oil from Pinus Koraiensis Pinecones Inhibits Gastric Cancer Cells via the HIPPO/YAP Signaling Pathway.

Zhang Y, Xin C, Qiu J, Wang Z
Molecules (Basel, Switzerland) 2019 Oct 25;24(21)

---

The CalcR-PKA-Yap1 Axis Is Critical for Maintaining Quiescence in Muscle Stem Cells.

Zhang L, Noguchi YT, Nakayama H, Kaji T, Tsujikawa K, Ikemoto-Uezumi M, Uezumi A, Okada Y, Doi T, Watanabe S, Braun T, Fujio Y, Fukada SI
Cell reports 2019 Nov 19;29(8):2154-2163.e5

---

CLDN6 promotes tumor progression through the YAP1-snail1 axis in gastric cancer.

Yu S, Zhang Y, Li Q, Zhang Z, Zhao G, Xu J
Cell death & disease 2019 Dec 11;10(12):949

---

Myricetin Suppresses the Propagation of Hepatocellular Carcinoma via Down-Regulating Expression of YAP.

Li M, Chen J, Yu X, Xu S, Li D, Zheng Q, Yin Y
Cells 2019 Apr 17;8(4)

---

YAP triggers the Wnt/β-catenin signalling pathway and promotes enterocyte self-renewal, regeneration and tumorigenesis after DSS-induced injury.

Deng F, Peng L, Li Z, Tan G, Liang E, Chen S, Zhao X, Zhi F
Cell death & disease 2018 Feb 2;9(2):153

---

Large tumor suppressor 2, LATS2, activates JNK in a kinase-independent mechanism through ASK1.

Rusnak L, Tang C, Qi Q, Mo X, Fu H
Journal of molecular cell biology 2018 Dec 1;10(6):549-558

---

A comprehensive evaluation of Hippo pathway silencing in sarcomas.

Merritt NM, Fullenkamp CA, Hall SL, Qian Q, Desai C, Thomason J, Lambertz AM, Dupuy AJ, Darbro B, Tanas MR
Oncotarget 2018 Aug 3;9(60):31620-31636

---

Expression of tumoral FOXP3 in gastric adenocarcinoma is associated with favorable clinicopathological variables and related with Hippo pathway.

Suh JH, Won KY, Kim GY, Bae GE, Lim SJ, Sung JY, Park YK, Kim YW, Lee J
International journal of clinical and experimental pathology 2015;8(11):14608-18

---

MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1).

Sun D, Yu F, Ma Y, Zhao R, Chen X, Zhu J, Zhang CY, Chen J, Zhang J
The Journal of biological chemistry 2013 Mar 29;288(13):9508-18

Western blot

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

SGC-7901 cells were subjected to SDS PAGE followed by western blot with 20276-1-AP(LATS2-Specific antibody) at dilution of 1:500

Sample type

cell line

Immunohistochemistry

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

Immunohistochemical of paraffin-embedded human heart using 20276-1-AP(LATS2-Specific antibody) at dilution of 1:100 (under 10x lens)

Sample type

tissue

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

Immunohistochemical of paraffin-embedded human heart using 20276-1-AP(LATS2-Specific antibody) at dilution of 1:100 (under 40x lens)

Sample type

tissue

Flow cytometry

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

The LATS2-Specific antibody from Proteintech is a rabbit polyclonal antibody to a peptide of human LATS2-Specific. This antibody recognizes human antigen. The LATS2-Specific antibody has been validated for the following applications: ELISA, WB, IHC, FC analysis.

Appendix

20276-1-AP.pdf

Show more